maxidrol
lex ano, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių tepalas - 1 mg/3500 tv/6000 tv/g - dexamethasone and antiinfectives
maxidrol
ideal trade links, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių tepalas - 1 mg/3500 tv/6000 tv/g - dexamethasone and antiinfectives
maxitrol
lex ano, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių lašai (suspensija) - 1 mg/3500 tv/6000 tv/ml - dexamethasone and antiinfectives
polygynax
limedika, uab - neomicino sulfatas/polimiksino b sulfatas/nistatinas - makšties minkštosios kapsulės - 35000 tv/35000 tv/100000 tv - nystatin, combinations
polygynax
medlinija, uab - neomicino sulfatas/polimiksino b sulfatas/nistatinas - makšties minkštosios kapsulės - 35000 tv/35000 tv/100000 tv - nystatin, combinations
polygynax
lex ano, uab - neomicino sulfatas/polimiksino b sulfatas/nistatinas - makšties minkštosios kapsulės - 35000 tv/35000 tv/100000 tv - nystatin, combinations
polygynax
laboratoire innotech international - neomicino sulfatas/polimiksino b sulfatas/nistatinas - makšties minkštosios kapsulės - 35000 tv/35000 tv/100000 tv - nystatin, combinations
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicino hidrochloridas - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antinavikiniai vaistai - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
doxolipad
tlc biopharmaceuticals b.v. - doksorubicino hidrochloridas - breast neoplasms; ovarian neoplasms - antinavikiniai vaistai - gydant krūties ir kiaušidžių vėžį.
ramdacordia
sandoz d.d. - ramiprilis/amlodipinas - kietosios kapsulės - 10 mg/10 mg; 5 mg/10 mg; 5 mg/5 mg; 2,5 mg/2,5 mg; 10 mg/5 mg - ramipril and amlodipine